Therapeutic implications for interferon-alpha in arthritis.
Ina
I
Kötter
Nicole
N
Stübiger
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology*; D006023:Glycoproteins / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000494:pharmacology*; D016898:Interferon-alpha / Q000276:immunology / Q000494:pharmacology*; D053590:Interleukin 1 Receptor Antagonist Protein; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000096:biosynthesis / Q000235:genetics; D018124:Receptors, Tumor Necrosis Factor / Q000096:biosynthesis / Q000187:drug effects; D012795:Sialoglycoproteins / Q000096:biosynthesis / Q000187:drug effects; D013583:Synovial Membrane / Q000187:drug effects* / Q000276:immunology
D006023:Glycoproteins; C507763:IL1RN protein, human; D007155:Immunologic Factors; D016898:Interferon-alpha; D053590:Interleukin 1 Receptor Antagonist Protein; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; D012795:Sialoglycoproteins; C506030:TNFRSF11B protein, human